- Report
- February 2024
- 113 Pages
Global
From €4279EUR$4,750USD£3,775GBP
- Report
- April 2023
- 147 Pages
Global
From €4458EUR$4,949USD£3,934GBP
- Report
- December 2022
- 142 Pages
Global
From €4008EUR$4,450USD£3,537GBP
- Report
- December 2019
- 120 Pages
Global
From €3333EUR$3,700USD£2,941GBP
- Report
- July 2025
- 200 Pages
India
From €2512EUR$2,789USD£2,217GBP
- Report
- June 2023
- 120 Pages
Asia Pacific
From €3485EUR$3,869USD£3,075GBP
- Report
- May 2023
- 140 Pages
Global
From €4458EUR$4,949USD£3,934GBP
- Report
- April 2023
- 147 Pages
Global
From €4458EUR$4,949USD£3,934GBP
- Report
- March 2023
- 147 Pages
Global
From €4458EUR$4,949USD£3,934GBP
- Report
- April 2023
- 119 Pages
Global
From €4054EUR$4,500USD£3,577GBP
- Report
- April 2024
- 140 Pages
Global
From €4476EUR$4,969USD£3,949GBP
- Report
- July 2024
- 151 Pages
Global
From €3254EUR$3,613USD£2,871GBP
€3828EUR$4,250USD£3,378GBP
- Report
- May 2024
- 119 Pages
Global
From €1757EUR$1,950USD£1,550GBP
- Report
- December 2023
- 76 Pages
Global
From €7202EUR$7,995USD£6,355GBP
- Report
- December 2022
- 110 Pages
Global
From €1757EUR$1,950USD£1,550GBP
- Report
- June 2024
- 220 Pages
Global
From €4499EUR$4,995USD£3,970GBP
- Report
- January 2024
- 106 Pages
Global
€4499EUR$4,995USD£3,970GBP
- Report
- July 2024
- 158 Pages
Global
From €3254EUR$3,613USD£2,871GBP
€3828EUR$4,250USD£3,378GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4414EUR$4,900USD£3,895GBP
- Report
- August 2023
- 300 Pages
Europe
From €4414EUR$4,900USD£3,895GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more